Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | - |
Domain |
PF02893 GRAM domain |
Function |
May play a role in meotic resumption and pronuclear formation, mediated by a WW domain-signaling pathway during fertilization. |
Biological Process |
GO:0006997 nucleus organization GO:0007338 single fertilization GO:0007343 egg activation GO:0009566 fertilization GO:0035038 female pronucleus assembly GO:0035039 male pronucleus assembly GO:0051321 meiotic cell cycle |
Molecular Function |
GO:0050699 WW domain binding |
Cellular Component |
GO:0033011 perinuclear theca |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between WBP2NL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of WBP2NL in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of WBP2NL in various data sets.
|
Points in the above scatter plot represent the mutation difference of WBP2NL in various data sets.
|
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WBP2NL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WBP2NL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WBP2NL. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WBP2NL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of WBP2NL expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between WBP2NL and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | WBP2NL |
Name | WBP2 N-terminal like |
Aliases | FLJ26145; MGC26816; PAWP; postacrosomal sheath WW domain-binding protein; WW domain-binding protein 2-like |
Chromosomal Location | 22q13.2 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting WBP2NL collected from DrugBank database. |
There is no record. |